MCRR Refugees Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : MCRR Refugees

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Graham Marshman who wrote (68)	7/6/1998 6:18:00 PM
From: out_of_the_loop	Read Replies (2) of 582

I am not sure we are talking about the same things here. The release says that they made DNA from RNA. This has been done a lot with PCR and related techniques. The fact that this is now done in vivo may indeed be new, but the actual significance is not defined by the report, IMO. The release does not say whether there was cell death or if they did anything else other than find the cDNA (c=cloned). To prove that the experiment was TOTALLY successful, I would maintain that they would eventually have to: 1. prove they cloned the DNA. 2. prove the cell can make that DNA's RNA. 3. prove that the new RNA makes the correct protein in the cell. 4. prove that the manufactured protein repairs the defect that was the problem to begin with. 5. prove that the cells do not do anything to successfully reverse the effects of the new DNA. 6. prove that subsequent cells in the cell line (skin, for example) conserve (that is, keep reproducing) the new DNA into their progeny. While I do not pretend to be a molecular biologist, I interpret this as an early step in this process. I welcome the opportunity to learn through differing opinions. hde CSI Researchers Express ssDNA In Vivo HOUSTON - July 4, 1998 - Cryogenic Solutions, Inc. (OTC BB: CYGS) announced the expression of sequence specific oligodeoxyribonucleotides from a ribonucleic acid expression vector. This in vivo expression of single-stranded DNA (ssDNA) that is complementary to an RNA template encoded in a vector was accomplished under a sponsored research agreement by CSI. The option of having flanking regions present or absent in the expressed ssDNA product is an additional useful property of this work. CSI holds the patent rights of this and related technology developed under the sponsored research agreement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next